A continuous-time multistate Markov model to describe the occurrence and severity of diarrhea events in metastatic breast cancer patients treated with lumretuzumab in combination with pertuzumab and paclitaxel-Reference-Cited by-同舟云学术

A continuous-time multistate Markov model to describe the occurrence and severity of diarrhea events in metastatic breast cancer patients treated with lumretuzumab in combination with pertuzumab and paclitaxel

Published:2018-06-18 Issue:3 Volume:82 Page:395-406
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Xu Chao,Ravva Patanjali,Dang Jun Steve,Laurent Johann,Adessi Céline,McIntyre Christine,Meneses-Lorente Georgina,Mercier François^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/article/10.1007/s00280-018-3621-9/fulltext.html

Reference25 articles.

1. Campbell MR, Amin D, Moasser MM (2010) HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy. Clin Cancer Res 16:1373–1383. https://doi.org/10.1158/1078-0432.CCR-09-1218

2. Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, Tausch C, Seo JH, Tsai Y-F, Ratnayake J, McNally V, Ross G, Cortés J (2013) Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol 24:2278–2284. https://doi.org/10.1093/annonc/mdt182

3. Gianni L, Pienkowski T, Im Y-H, Tseng L-M, Liu M-C, Lluch A, Staroslawska E, de la Haba-Rodriguez J, Im S-A, Pedrini J, Poirier B, Morandi P, Semiglazov V, Srimunnimit V, Bianchi GV, Magazzu D, McNally V, Douthwaite H, Ross G, Valagussa P (2016) 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, infl ammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Onco 17:791–800. https://doi.org/10.1016/S1470-2045(16)00163-7

4. Von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, Bines J, Gelber RD, Piccart M, Baselga J (2017) Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med 377:122–131. https://doi.org/10.1056/NEJMoa1703643

5. Swain SM, Baselga J, Kim S-B, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero J-M, Schneeweiss A, Heeson S, Clark E, Ross G, Benyunes M, Cortés J (2015) Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 372:724–734. https://doi.org/10.1056/NEJMoa1413513

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exposure–response modeling of peficitinib efficacy in patients with rheumatoid arthritis;Pharmacology Research & Perspectives;2021-04-30

2. Assessment of diarrhea as side effect of oral targeted antineoplastic agents in clinical practice;Supportive Care in Cancer;2021-01-28

3. Personalized pharmacotherapy in oncology: Application of pharmacokinetic-pharmacodynamic criteria;FARM HOSP;2021

4. Analysis of Longitudinal‐Ordered Categorical Data for Muscle Spasm Adverse Event of Vismodegib: Comparison Between Different Pharmacometric Models;CPT: Pharmacometrics & Systems Pharmacology;2020-01-30